Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 2,958 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at approximately $3,089,766.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

TransMedics Group Stock Up 0.1 %

NASDAQ TMDX traded up $0.18 during trading on Thursday, reaching $143.80. 754,384 shares of the company’s stock traded hands, compared to its average volume of 830,882. TransMedics Group, Inc. has a 12-month low of $36.42 and a 12-month high of $177.37. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm has a market cap of $4.74 billion, a price-to-earnings ratio of -422.41 and a beta of 1.99. The company’s 50 day simple moving average is $156.09 and its two-hundred day simple moving average is $133.18.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. The company had revenue of $114.30 million for the quarter, compared to analyst estimates of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group’s revenue was up 117.7% compared to the same quarter last year. During the same period last year, the company posted ($0.03) earnings per share. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1.23 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TMDX. Fidelis Capital Partners LLC purchased a new position in TransMedics Group in the first quarter valued at about $35,000. International Assets Investment Management LLC bought a new stake in shares of TransMedics Group in the 2nd quarter valued at about $47,000. J.Safra Asset Management Corp grew its position in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares during the last quarter. Signaturefd LLC raised its stake in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares in the last quarter. Finally, Amalgamated Bank lifted its position in TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock valued at $168,000 after acquiring an additional 70 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald initiated coverage on TransMedics Group in a report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price target on the stock. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. TD Cowen upped their price target on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, Robert W. Baird began coverage on shares of TransMedics Group in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $200.00 target price on the stock. One investment analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $174.30.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.